Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Post by healthstock1234on Oct 23, 2015 12:35pm
103 Views
Post# 24221066

a cross-border law firm has commenced an investigation VRX

a cross-border law firm has commenced an investigation VRXShareholder Alert: Morganti Legal Announces Investigation of Valeant Pharmaceuticals International Inc. (VRX)less than 1 minute ago by CNW Group

Morganti Legal, a cross-border law firm focused on representing investors, has commenced an investigation into potential violations of securities laws by Valeant Pharmaceuticals International Inc. (TSX and NYSE: "VRX") in respect of allegations that Valeant may have released materially misleading business information to the investing public including potentially inflating revenues by recording intercompany sales in its revenue figures.

On October 19, 2015, Southern Investigative Reporting Foundation (SIRF) issued a report on Valeant revealing an undisclosed relationship between the Company and specialty pharmacy Philidor RX Services. Upon release of this news, Valeant's share price on the TSX fell $14.35 per share from the previous trading day's close to close at $213.05 per share.

On October 21, 2015, Citron Research issued a subsequent report on Valeant, which alleged, amongst other things, that Valeant and Philidor maintain phantom pharmacies to improperly recognize and record revenue from the sale of drugs, or in order to avoid scrutiny from auditors. Upon release of this news, Valeant's share price on the TSX dropped 40% during intraday trading, and ultimately fell $36.64 per share to close the day at $154.21.

Investors who purchased shares of Valeant Pharmaceuticals International Inc. on the Toronto Stock Exchange on or before October 21, 2015 are encouraged to stay informed and protect their rights. You may contact Morganti Legal at (888) 226-0845 FREE or by email at info@morgantilegal.com for further information.

None of the allegations have been adjudicated in court at this time.

Morganti Legal is comprised of experienced securities lawyers that investigate, litigate and resolve economic and financial disputes. You may learn more about Morganti Legal at www.morgantilegal.com. The Firm currently represents investors that purchased securities of Allied Nevada Gold Corp, BP plc, Detour Gold Corporation, Ithaca Energy Limited, MDC Partners, Inc., Silvercorp Metals Inc., and Tesco plc.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Trilogy Class Actions

To view this news release in HTML formatting, please use the following URL: https://www.newswire.ca/en/releases/archive/October2015/23/c3322.html

SOURCE: Trilogy Class Actions

<< Previous
Bullboard Posts
Next >>